Ascletis Pharma Inc. (Ascletis-B) filed a Next Day Disclosure Return with the Hong Kong Stock Exchange on 30 June 2026, detailing the following:

Key Takeaways

1. Latest Buyback • On 30 June 2026, the company repurchased 145,000 ordinary shares on the open market. • Transaction price range: HKD 10.35–10.51 per share, with a volume-weighted average of about HKD 10.49. • Cash outlay: approximately HKD 1.52 million.

2. Capital Structure Unchanged for Reporting Date • Issued shares (excluding treasury shares) remained at 1,061,370,845. • Treasury shares stood at 7,084,210, leaving total issued shares at 1,068,455,055. • No new shares were issued during the period.

3. Cumulative Repurchases Pending Cancellation • From 3 April 2025 through 30 June 2026, Ascletis has bought back 9,531,000 shares that were not yet cancelled as of the reporting date. • These pending cancellations represent roughly 0.90 % of the company’s outstanding share base.

4. Repurchase Mandate Capacity • Shareholders renewed the buyback mandate on 29 June 2026, authorising up to 106,137,084 shares (10 % of the issued share capital at that date) to be repurchased. • The 145,000 shares bought on 30 June 2026 account for 0.0137 % of issued shares as at the mandate date, leaving over 105 million shares available under the current authority.

5. Post-Buyback Restrictions • In line with Main Board Rule 10.06(3), Ascletis is subject to a moratorium on issuing new shares or disposing of treasury shares until 30 July 2026.

All repurchases were executed in compliance with Hong Kong Listing Rules, and there were no adjustments to previously disclosed information in the company’s explanatory statement dated 8 June 2026.